{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:58Z","timestamp":1772166238241,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Raltegravir (RAL) has favorable tolerability and safety profile, with few and manageable drug interactions. The use of RAL 1200\u00a0mg once daily (qd) for first-line therapy is well established. We assessed efficacy and safety of RAL 1200\u00a0mg qd, as part of triple combined antiretroviral therapy (cART), for maintenance strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The QDISS trial (NCT03195452) was a 48-week multicenter, single-arm, open-label study designed to evaluate the ability of 2 NRTIs\u2009+\u2009RAL 1200\u00a0mg qd to maintain virological suppression in HIV-1 infected subjects on a stable cART with 2 NRTIs and a third agent for at least 6\u00a0months. The primary endpoint was the proportion of participants with HIV-1 RNA\u2009&lt;\u200950 copies\/mL at week 24, by the FDA snapshot algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 100 participants 91% maintained viral suppression (95% CI: 83.6\u201395.8) at week 24 and 89% (81.2\u201394.4) at week 48. At week 24, there was one virological failure, without emergence of resistance-associated mutation and 10 participants had discontinued, 4 because of adverse events (AEs). Over 48\u00a0weeks, 7 AEs of grade 3\u20134 were reported, one possibly study-drug related (spontaneous abortion). BMI remained stable regardless of previous therapy or baseline BMI category. Over 48\u00a0weeks, total cholesterol (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023) and LDL-cholesterol (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009) decreased, lifestyle and ease subscale significantly improved (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). The quality of life and Patients Reported Outcomes (PROs) also improved at W12 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RAL 1200\u00a0mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1 infected subjects, with good safety profile and improved lipid profile and patient reported outcomes.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration:<\/jats:italic>\n                      Clinical trials.gov NCT03195452 and EudraCT 2016-003702-13.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-022-00428-5","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T06:02:33Z","timestamp":1642226553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Raltegravir 1200\u00a0mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial"],"prefix":"10.1186","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct03195452","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nolwenn","family":"Hall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Jobert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Cua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firouz\u00e9","family":"Bani-Sadr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Hocqueloux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Merrien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoto","family":"Hikombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Andr\u00e9-Garnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Gaultier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the QDISS Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bollengier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Guimard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Leautez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Blanchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Cotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Perpoint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Anne","family":"Trabaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Biron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Ferr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Flet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Reliquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Rodalec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christ\u00e8le","family":"Volteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Breaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Pugli\u00e8se","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"De Dieuleveult","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Prazuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Bachelard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Legac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Kalambay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Slama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Viard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9my","family":"Lourenco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Ktorza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Palich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luminita","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariagrazia","family":"Tateo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Zeggagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Brodard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Hentzien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Kmiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohan","family":"N\u2019Guyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fa\u00efza","family":"Ajana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Bocket","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Huleux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Meybeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"428_CR1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infectedadults and Adolescents. Department of Health and Human Services; 2019. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf. Accessed May 1, 2021"},{"key":"428_CR2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2020.17025","volume":"324","author":"MS Saag","year":"2020","unstructured":"Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel. JAMA. 2020;324:1651\u201369.","journal-title":"JAMA"},{"key":"428_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.idc.2019.04.005","volume":"33","author":"KM Erlandson","year":"2019","unstructured":"Erlandson KM, Karris MY. HIV and aging: reconsidering the approach to management of comorbidities. Infect Dis Clin North Am. 2019;33:769\u201386.","journal-title":"Infect Dis Clin North Am"},{"key":"428_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2165\/11204590-000000000-00000","volume":"70","author":"JD Croxtall","year":"2010","unstructured":"Croxtall JD, Scott LJ. Raltegravir: in treatment-naive patients with HIV-1 infection. Drugs. 2010;70:631\u201342.","journal-title":"Drugs"},{"key":"428_CR5","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S2352-3018(17)30128-5","volume":"4","author":"P Cahn","year":"2017","unstructured":"Cahn P, Kaplan R, Sax PE, et al. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017;4:e486-494.","journal-title":"Lancet HIV"},{"key":"428_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","volume":"9","author":"A Woodcock","year":"2006","unstructured":"Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2006;9:320\u201333.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"428_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1023\/A:1013050904635","volume":"10","author":"A Woodcock","year":"2001","unstructured":"Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2001;10:517\u201331.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"key":"428_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/QAI.0b013e31824be3f2","volume":"59","author":"M Duracinsky","year":"2012","unstructured":"Duracinsky M, Lalanne C, Le Coeur S, et al. Psychometric validation of the PROQOL-HIV questionnaire, a new health-related quality of life instrument-specific to HIV disease. J Acquir Immune Defic Syndr. 2012;59:506\u201315.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"428_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735\u201343.","journal-title":"Lancet"},{"key":"428_CR10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","volume":"374","author":"JL Lennox","year":"2009","unstructured":"Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796\u2013806.","journal-title":"Lancet"},{"key":"428_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/QAI.0000000000001723","volume":"78","author":"P Cahn","year":"2018","unstructured":"Cahn P, Sax PE, Squires K, et al. Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: week 96 results from oncemrk, a randomized, double-blind, noninferiority trial. J Acquir Immune Defic Syndr. 2018;78:589\u201398.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"428_CR12","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"ES Daar","year":"2018","unstructured":"Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e347-356.","journal-title":"Lancet HIV"},{"key":"428_CR13","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"J-M Molina","year":"2018","unstructured":"Molina J-M, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e357-365.","journal-title":"Lancet HIV"},{"key":"428_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","volume":"375","author":"JJ Eron","year":"2010","unstructured":"Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396\u2013407.","journal-title":"Lancet"},{"key":"428_CR15","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","volume":"24","author":"E Mart\u00ednez","year":"2010","unstructured":"Mart\u00ednez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697\u2013707.","journal-title":"AIDS"},{"key":"428_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1097\/QAD.0000000000001590","volume":"31","author":"L Elzi","year":"2017","unstructured":"Elzi L, Erb S, Furrer H, et al. Adverse events of dolutegravir and raltegravir. AIDS. 2017;31:1853\u20138.","journal-title":"AIDS"},{"key":"428_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.24875\/AIDSRev.19000023","volume":"21","author":"C Hoffmann","year":"2019","unstructured":"Hoffmann C, Llibre JM. Neuropsychiatric events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019;21:4\u201310.","journal-title":"AIDS Rev"},{"key":"428_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2012.08.010","volume":"225","author":"M Saumoy","year":"2012","unstructured":"Saumoy M, Sanchez-Quesada JL, Martinez E, et al. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir. Spiral substudy. Atherosclerosis. 2012;225:200\u20137.","journal-title":"Atherosclerosis"},{"key":"428_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019;381:803\u201315.","journal-title":"N Engl J Med"},{"key":"428_CR20","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy\u202f: risk factors in randomized comprataive clinical trials. Clin Infect Dis. 2020;71:1380\u20139.","journal-title":"Clin Infect Dis"},{"key":"428_CR21","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","volume":"71","author":"JE Lake","year":"2020","unstructured":"Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor based antiretroviral therapy. Clin Infect Dis. 2020;71:e471-477.","journal-title":"Clin Infect Dis"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00428-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-022-00428-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00428-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T06:08:20Z","timestamp":1642226900000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-022-00428-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1186\/s12981-022-00428-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-823865\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Ethics Committee of Est III (17.04.06), and authorized by the French National Agency for the Safety of Medicines (ANSM 170133A-41). All participants gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests in relation to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}